<div id="content">
				<a id="top"></a>
	        		        	<h1 id="firstHeading" class="firstHeading">Drugsandbrain:Glossary</h1>
				<div id="bodyContent">
		            <h3 id="siteSub">From Coursera</h3>
		            <div id="contentSub"></div>
		            		            		            					<!-- start content -->
					<div lang="en" dir="ltr" class="mw-content-ltr"><p>Glossary for new or technical terms used in class lectures.</p>
<table id="toc" class="toc"><tr><td><div id="toctitle"><h2>Contents</h2></div>
<ul>
<li class="toclevel-1"><a href="#A.2C_B"><span class="tocnumber">1</span> <span class="toctext">A, B</span></a></li>
<li class="toclevel-1"><a href="#C.2C_D"><span class="tocnumber">2</span> <span class="toctext">C, D</span></a></li>
<li class="toclevel-1"><a href="#E.2C_F"><span class="tocnumber">3</span> <span class="toctext">E, F</span></a></li>
<li class="toclevel-1"><a href="#G.2C_H"><span class="tocnumber">4</span> <span class="toctext">G, H</span></a></li>
<li class="toclevel-1"><a href="#I.2C_J"><span class="tocnumber">5</span> <span class="toctext">I, J</span></a></li>
<li class="toclevel-1"><a href="#K.2C_L"><span class="tocnumber">6</span> <span class="toctext">K, L</span></a></li>
<li class="toclevel-1"><a href="#M.2C_N"><span class="tocnumber">7</span> <span class="toctext">M, N</span></a></li>
<li class="toclevel-1"><a href="#O.2C_P"><span class="tocnumber">8</span> <span class="toctext">O, P</span></a></li>
<li class="toclevel-1"><a href="#Q.2C_R"><span class="tocnumber">9</span> <span class="toctext">Q, R</span></a></li>
<li class="toclevel-1"><a href="#S.2C_T"><span class="tocnumber">10</span> <span class="toctext">S, T</span></a></li>
<li class="toclevel-1"><a href="#U.2C_V.2C_W"><span class="tocnumber">11</span> <span class="toctext">U, V, W</span></a></li>
<li class="toclevel-1"><a href="#X.2C_Y.2C_Z"><span class="tocnumber">12</span> <span class="toctext">X, Y, Z</span></a></li>
</ul>
</td></tr></table>
<h1> <span class="mw-headline" id="A.2C_B">A, B</span></h1>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Adeno-associated_virus">AAV adeno-associated virus</a></strong>  </p>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Agonist">agonist</a></strong>
<ul><li> a drug response that is acting. There are full, partial and inverse agonists (discussed in lecture 11)</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Allosteric_regulation">Allosteric</a></strong>
<ul><li> Relating to the ability of a molecule (such as a drug) to bind to a protein (such as an ion channel) at a site other than the functional or ‘active’ site of that protein, and thereby alter or regulate the shape and function of that protein.  </p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Anhedonia">Anhedonia</a></strong></p>
<ul>
<li>loss of pleasure  </li>
</ul>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Receptor_antagonist">antagonist</a></strong><br />
<ul><li> a drug that display no efficacy to activate the receptors they bind to (discussed in lecture 11)</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Neuregulin#ARIA">ARIA Acetylcholine Receptor Inducing Activity</a></strong>
<ul><li> A type of neuregulin, which is a protein that releases <a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Epidermal_growth_factor_family">(EGF) Epidermal growth factor</a> Some schizophrenia associated genes may be the neuregulin (as discussed in mini lecture 48)</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Brain-derived_neurotrophic_factor">BDNF Brain-derived Neurotrophic Factor</a></strong>    </p>
<hr />
<h1> <span class="mw-headline" id="C.2C_D">C, D</span></h1>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Cooperativity">Cooperativity</a></strong><br />
<ul><li> indicates that after the first agonist is bound, the second is more likely to bind (discussed in lecture 11)</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Cyclic_adenosine_monophosphate">cyclic AMP, cAMP </a></strong><br />
<ul><li> a key intracellular messenger (discussed in lecture 19)</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/CREB">CREB cyclic AMP calcium responsive element binder</a></strong>  </p>
<ul>
<li>phosphorylated CREB binds to cyclic AMP calcium responsive element (CRE) to enable switching on and off some genes (discussed in lecture 21)</li>
</ul>
<p><strong><a rel="nofollow" class="external text" href="http://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/">DALY disability-adjusted life year </a></strong><br />
 DALY = YLL + YLD<br />
 where: YLL = Years of Life Lost due to premature mortality in the population, YLD = Years Lost due to Disability   </p>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Dirac_delta_function">Delta function (Dirac’s Delta function)</a></strong></p>
<ul>
<li>A mathematical ‘graph’ or distribution designed to represent an impulse or a very brief and localised event. The delta function has certain mathematical properties which make it useful in the modelling of physical and biological processes.  (discussed in lecture 12)</li>
</ul>
<blockquote>
  <p>The delta function can be used to represent the synchronous and abrupt release of neurotransmitter into the synaptic cleft,  triggered by calcium influx into the pre-synaptic terminal.  </p>
</blockquote>
<p><strong>Drug</strong>  </p>
<ul>
<li>A substance used as a medication or in the preparation of medication.  </li>
<li>According to the Food, Drug, and Cosmetic Act<br />
(1) a substance recognized in an official pharmacopoeia or formulary<br />
(2) a substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease<br />
(3) a substance other than food intended to affect the structure or function of the body  </li>
<li>Something and often an illegal substance that causes addiction, habituation, or a marked change in consciousness  </li>
</ul>
<p><strong>DSM IV</strong><br />
<ul><li> <a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Diagnostic_and_Statistical_Manual_of_Mental_Disorders">Diagnostic and Statistical Manual of Mental Disorders, fourth edition</a> </p>
</li></ul>

<hr />
<h1> <span class="mw-headline" id="E.2C_F">E, F</span></h1>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/EC50">EC50</a></strong><br />
<ul><li> half maximal concentration of the drug, as on a dose-response relationship graph (discussed in lecture 11)</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Intrinsic_activity">efficacy</a></strong><br />
<ul><li> ability of a drug receptor to produce a maximal response (discussed in lecture 11)</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Epitope">Epitope</a></strong>
<ul><li> Molecule or part of a molecule that can be recognized by an antibody (discussed in lecture 36) </p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Excitatory_postsynaptic_potential">excitatory postsynaptic potential (EPSP)</a></strong><br />
<ul><li> </p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Functional_magnetic_resonance_imaging">fMRI functional Magnetic Resonance Imaging</a></strong><br />
MRI procedure that measures brain activity by detecting associated changes in blood flow  </p>
<hr />
<h1> <span class="mw-headline" id="G.2C_H">G, H</span></h1>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/G_protein-coupled_receptor">G protein-coupled receptors (GPCR)</a></strong><br />
<ul><li>  protein family of receptors that sense molecules outside the cell and activate inside signal transduction pathways and, ultimately, cellular responses. (discussed in lectures 17 to 21)</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Glial_cell_line-derived_neurotrophic_factor">GDNF glial cell derived neurotrophic factor</a></strong> </p>
<p><strong>Gi - inhibitory G protein pathway</strong><br />
<ul><li> Gi-Coupled receptors usually inhibit neurons, slow neuronal firing and decrease the synaptic release of transmitters (discussed in lecture 18)</p>
</li></ul>

<p><strong>Gq - calcium { Ca2+} mobilizing  G protein pathway</strong><br />
<ul><li> this pathway is that it leads from calcium in the endoplasmic reticulum to calcium in the cytosol (discussed in lecture 20)</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Granule_cells">Granule cell</a></strong><br />
<ul><li> excitatory cells that release glutamate, composing 10% of all of the cells in the brain (discussed in lecture 14)  </p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Green_fluorescent_protein">Green fluorescent protein (GFP)</a></strong>  </p>
<p><strong>Gs - stimulatory G protein pathway</strong><br />
<ul><li> Gs coupled receptors often stimulate neurons and other cells (this is the topic of lecture 19)</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Heterotrimeric_G_protein">Heterotrimeric G protein</a></strong><br />
<ul><li> G protein with &#945;, a &#946;, and a &#947; subunits (discussed in lecture 18)  </p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Hill_coefficient">Hill coefficient</a></strong>
<ul><li> how cooperative the dose response relation looks (discussed in lecture 11)  </p>
</li></ul>

<hr />
<h1> <span class="mw-headline" id="I.2C_J">I, J</span></h1>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Inhibitory_postsynaptic_potential">inhibitory postsynaptic potential (IPSP)</a></strong><br />
<ul><li> a synaptic potential that drives the postsynaptic neuron to generate less spikes (discussed in lecture 14)</p>
</li></ul>

<hr />
<h1> <span class="mw-headline" id="K.2C_L">K, L</span></h1>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Kinase">kinase</a></strong><br />
<ul><li> enzyme that transfer a high energy phosphate bond from ATP to a serine or threonine side chain on a protein, that is a kinase phosphorylates a protein- (discussed in lecture 19)</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Gene_knockin">Knock-in</a></strong>  </p>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Gene_knockout">knockout </a></strong>  </p>
<hr />
<h1> <span class="mw-headline" id="M.2C_N">M, N</span></h1>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Monoamine_oxidase_inhibitor">MAOI Monoamine oxidase inhibitor</a></strong><br />
<ul><li> drug used in the treatment of depression</p>
</li></ul>

<p><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/MicroRNA">microRNA</a></p>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Monoamine_neurotransmitter">Monoamine neurotransmitter</a></strong><br />
<ul><li>  neurotransmitters that contain one amino group that is connected to an aromatic ring such as  Dopamine, Norepinephrine, and Serotonin.</p>
</li></ul>

<p><strong>multifactorial genes</strong>
<ul><li> several types of collections of mutations, all come together to form one clinical phenotype (as discussed in mini lecture 48)</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Symptom#Positive_and_negative_symptoms">Negative Symptom</a></strong><br />
<ul><li> symptoms that are not present or that are diminished in the affected persons but are normally found in healthy persons.</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Neurotransmitter">Neurotransmitter</a></strong>    </p>
<hr />
<h1> <span class="mw-headline" id="O.2C_P">O, P</span></h1>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Off-label_use">Off-label</a></strong>
<ul><li>  prescribing a drug for an unapproved indication,  or in an unapproved age group, unapproved dose or unapproved form of administration</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Penetrance">Penetrance</a></strong>
<ul><li>  The penetrance of a disease-causing mutation is the proportion of individuals with the mutation who exhibit clinical symptoms.</p>
</li></ul>

<blockquote>
  <p>Example: The penetrance of schizophrenia among identical twins (genetically identical) is only 50%, not 100%. Thus, schizophrenia is partially penetrant. (as discussed in mini lecture 48)</p>
</blockquote>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Phosphodiesterase">phosphodiesterase</a></strong><br />
<ul><li> enzymes that breaks the diester bond in intracellular messengers, such as cyclic AMP or cyclic GMP. It is inhibited by caffeine and theophylline in coffee and tea. Phosphodiesterase inhibitors sometimes prolongs the life of intracellular messengers.  (discussed in lecture 19)</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Phosphorylation">phosphorylation</a></strong>
<ul><li> phosphorylation turns many protein enzymes on and off, thereby altering their function and activity. In Drugs and the Brain, we discussed the action of kinases, such as PKA, that (discussed in lecture 19)</p>
</li></ul>

<p><strong>Plasticity (Neural plasticity) or <a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Neuroplasticity">Neuroplasticity</a></strong></p>
<ul>
<li>The long-term adaptations of neurons to the sustained short-term actions of a drug.<br />
&gt; Example: The clinical effect of the SSRI class of antidepressants (such as fluoxetine and mirtazepine) has a delayed onset. This is probably because neural plasticity is the means by which these drugs improve the individual’s mood and functioning.<br />
&gt; In healthy individuals neural plasticity is associated with learning and memory. Some disease conditions (such as chronic pain syndromes) may be caused by abnormal neural plasticity.<br />
&gt; These changes may be brought about by phosphorylation of neuronal proteins and regulation of gene transcription or expression or by changes in synaptic function.  </li>
</ul>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Polygene">Polygenic</a></strong>
<ul><li> The disease occurs only if several genotypes are present together. (as discussed in mini lecture 48)</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Symptom#Positive_and_negative_symptoms">Positive Symptom</a></strong><br />
<ul><li> symptoms that most individuals do not normally experience but are present in the disorder.</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Prodrome">Prodrome</a></strong><br />
<ul><li> early symptom (or set of symptoms) that might indicate the start of a disease before specific symptoms occur.</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Protein_kinase_A">Protein kinase A (PKA)</a></strong><br />
<ul><li> protein kinase A (cyclic AMP activated protein kinase) (discussed in lecture 19)</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Proteolysis">Proteolytic cleavage, Proteolysis</a></strong></p>
<ul>
<li>Breakdown of a protein into peptides and amino acids.</li>
</ul>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Purkinje_cell">Purkinje cell</a></strong><br />
<ul><li> large neurons occurring in the cerebellum (discussed in lecture 14)  </p>
</li></ul>

<hr />
<h1> <span class="mw-headline" id="Q.2C_R">Q, R</span></h1>
<hr />
<h1> <span class="mw-headline" id="S.2C_T">S, T</span></h1>
<p><strong>Stochastic process</strong></p>
<ul>
<li>A random process.  A set of random values.  </li>
</ul>
<blockquote>
  <p>Example: Once a ligand-gated ion channel opens, the duration of time it remains open before closing again is not pre-determined. The closing time varies for the same channel on consecutive openings, and also varies between channels of the same kind. The channel closing event, in this example, can be mathematically modelled as a stochastic process.  </p>
</blockquote>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Selective_serotonin_reuptake_inhibitor">Selective Serotonin Reuptake Inhibitor</a></strong>    </p>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Single-nucleotide_polymorphism">SNP single-nucleotide polymorphism</a></strong>  </p>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Pars_compacta">SNr Substantia Nigra pars compacta </a></strong>  (discussed in lecture 13) </p>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Pars_reticulata">SNr Substantia Nigra pars reticulata </a></strong> (discussed in lecture 13)</p>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Single-photon_emission_computed_tomography">SPECT</a></strong><br />
<ul><li>  Single-photon emission computed tomography</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Subthalamic_nucleus">STn  subthalamic nucleus </a></strong>    </p>
<hr />
<h1> <span class="mw-headline" id="U.2C_V.2C_W">U, V, W</span></h1>
<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Vesicular_monoamine_transporter">VMAT vesicular monoamine transporter</a></strong><br />
<ul><li> a protein that  transport monoamines into the synaptic vesicles</p>
</li></ul>

<p><strong><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Ventral_tegmental_area">Ventral tegmental area (VTA)</a></strong><br />
<ul><li> dopaminergic  area of the brain (discussed in lecture 13)  </p>
</li></ul>

<hr />
<h1> <span class="mw-headline" id="X.2C_Y.2C_Z">X, Y, Z</span></h1>

<!-- 
NewPP limit report
Preprocessor node count: 48/1000000
Post-expand include size: 0/2097152 bytes
Template argument size: 0/2097152 bytes
Expensive parser function count: 0/100
-->


</div><div class="printfooter">
Retrieved from "<a href="https://share.coursera.org/wiki/index.php?title=Drugsandbrain:Glossary&amp;oldid=6768">https://share.coursera.org/wiki/index.php?title=Drugsandbrain:Glossary&amp;oldid=6768</a>"</div>
					<div id='catlinks' class='catlinks catlinks-allhidden'></div>					<!-- end content -->
									</div>
			</div>